Biotechnology

Rocket Pharma

Wedbush analyst reiterates buy rating on Rocket Pharmaceuticals

Rocket Pharma released FY2025 Q3 earnings on November 6, 2025 (EST), actual revenue USD 0 (forecast USD 250K), actual EPS USD -0.4511 (forecast USD -0.5043)

Rocket Pharma released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.629

Rocket Pharma released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 4.364 M), actual EPS USD -0.6207 (forecast USD -0.5567)

Rocket Pharma released FY2025 Semi-Annual earnings on August 7, 2025 (EST), with actual revenue of USD 0 and EPS of USD -1.1781

Rocket Pharma Reports Q2 Loss and Announces Layoffs

FDA Halts Rocket Pharmaceuticals RP-A501 Clinical Trial

FDA Imposes a Clinical Hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Key Trial

Gross Law Firm Notifies RCKT Shareholders of Class Action

Berger Montague PC investigates Rocket Pharmaceuticals' misleading RP-A501 gene therapy safety disclosures

Rosen Firm Urges Rocket Pharmaceuticals Investors to Seek Legal Consultation

Rocket Pharmaceuticals Sued for Failing to Timely Notify Study Suspension

Rocket Pharmaceuticals Stock Price Breaks Below Analyst Downgrade Ratings

Rosen Firm Urges Investors to Seek Legal Counsel for Rocket Pharmaceuticals Class Action

Rocket Pharmaceuticals Faces Class Action Lawsuit

Rosen Law Firm Reminds Rocket Pharmaceuticals of Deadline for Misleading Statement Lawsuit

Investor Rights Law Firm Reminds Rocket Pharmaceuticals of Securities Fraud Class Action Deadline

Rocket Pharmaceuticals Initiates RP-A701 Clinical Trial

Faruqi & Faruqi Investigating Rocket Pharmaceuticals Over Misleading Investors

Gross Law Firm Notifies Rocket Pharmaceuticals Shareholders of Class Action Suit

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap